ReviewEmerging microbes & infections2026
Global resurgence of Chikungunya virus: outbreak drivers and emerging solutions.
Review in Emerging microbes & infections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Virucidal Efficacy of Holder Pasteurization of Breast Milk in a Portable Device.Pathogens (Basel, Switzerland) · 2026Article
- Retinoic acid is a translation inhibitor against chikungunya virus both in vitro and invivo.Virologica Sinica · 2026Article
- Genomic epidemiology reveals the origins and transmission dynamics of chikungunya virus in China.Infectious diseases of poverty · 2026Article
- crRNA Truncation MinimizesJACS Au · 2026Article
- Article
- Seroprevalence of chikungunya virus in Colombo, Sri Lanka before the 2025 outbreak and implications for population susceptibility.medRxiv : the preprint server for health sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chikungunya virus (CHIKV) infections have raised increasing global concern. Recurrent outbreaks across diverse regions underscore the urgent need for proactive measures to prevent further epidemic spread. Key drivers - including high vector density, viral adaptive mutations, and delayed early intervention - have been addressed as critical factors promoting CHIKV emergence and transmission. Prompt case detection, integrated vector management, real-time genomic tracking, and water surveillance are pivotal to effective containment. Additionally, the availability of two licensed vaccines and several candidates in advanced clinical development offers new opportunities to protect vulnerable populations. We here emphasized the need to address the drivers of outbreaks and implement timely prevention and control measures, alongside deploying available vaccines to protect at-risk populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.